Drug intelligence / Profile preview

SSR181507

Development stage: Preclinical
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intraperitoneal (i.p.)

Overview

SSR181507 is a dopamine D₂ receptor antagonist/partial agonist and a serotonin 5-HT₁A receptor agonist. It is a novel tropanemethanamine benzodioxane derivative with high affinities for D₂-like and 5-HT₁A receptors. Initially developed by **Sanofi-Aventis**, SSR181507 has shown potential in treating schizophrenia and exhibits mixed antidepressant and anxiolytic activities in animal models.

Other names: 8-Azabicyclo(3.2.1)octane-3-methanamine, 8-benzoyl-N-(((2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-, (3-exo)-H276H25KW0H-276H25KW0H 276H25KW0UNII-H276H25KW0UNII-H-276H25KW0UNII-H 276H25KW0737743-26-9

Targets

DRD3 (Dopamine receptor D3)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on SSR181507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSR181507.

Explore the full profile